SEC Form SC 13G/A filed by Mana Capital Acquisition Corp. (Amendment)
$MAAQ
Consumer Electronics/Appliances
Industrials
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2022 | $14.00 | Speculative Buy | The Benchmark Company |
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
EFFECT - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
424B5 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
Mana Capital Acquisition Corp. ("Mana Capital") (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))), a publicly traded special purpose acquisition company, today announced that its registration statement on Form S-4, relating to the previously announced business combination between Mana Capital and Cardio Diagnostics, Inc. ("Cardio"), a pioneering precision cardiovascular testing company, has been declared effective by the U.S. Securities and Exchange Commission. Mana Capital has mailed the definitive proxy statement/prospectus (the "Proxy Statement") to stockholders of record as of the close of business on September 27, 2022. The Proxy Statement contains a notice and voting instruction form or a proxy ca
Mana Capital Acquisition Corp. (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))) (the "Company" or "Mana Capital"), a special purpose acquisition company ("Mana Capital"), announced today that for the purpose of consummating its previously announced business combination with Cardio Diagnostics, Inc. ("Cardio"), the Company has further extended the date by which it is required to complete a business combination for an additional period of one (1) month from September 26, 2022 to October 26, 2022, and that the amount of $216,667 has been deposited into the Company's trust account (the "Trust Account") in connection with the extension. The funds deposited into the Trust Account were provided by Cardio unde
Mana Capital Acquisition Corp. (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))) (the "Company" or "Mana Capital") today announced that its Board of Directors has approved a second extension of the period of time available to the Company to consummate its initial business combination by one month from September 26, 2022 to October 26, 2022 (the "Extension"), as permitted under the Company's amended and restated certificate of incorporation. In connection therewith, pursuant to the merger agreement, dated May 27, 2022, among the Company, Mana Merger Sub, Inc., Cardio Diagnostics, Inc. ("Cardio"), and Meeshanthini (Meesha) Dogan, as representative of the shareholders of Cardio, Cardio is expected to depo
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
3 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
The Benchmark Company initiated coverage of Mana Capital Acquisition Corp. with a rating of Speculative Buy and set a new price target of $14.00
SC 13G - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13D/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13D/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)